Back to Newsroom

StemCells, Inc. Announces Commencement of the Second Cohort of the Pathway(TM) Study in Cervical Spinal Cord Injury

NEWARK, Calif., June 4, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, announced today that it has enrolled its first subject in Cohort 2 of its Phase II Pathway Study. The study is designed to assess the efficacy of the Company’s proprietary HuCNS-SC® platform technology (purified human neural stem cells) for the treatment of cervical spinal cord injury. Cohort 2 will enroll 40 patients and forms the single-blinded controlled arm of the Phase II study. The primary efficacy outcome being tested in Cohort 2 is the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal cord.

Click here to read more